
- <Centre d'Information et de documentation du CRA Rhône-Alpes
- CRA
- Informations pratiques
		- 
						Adresse
						Centre d'information et de documentation Horaires
 du CRA Rhône-Alpes
 Centre Hospitalier le Vinatier
 bât 211
 95, Bd Pinel
 69678 Bron CedexLundi au Vendredi Contact
 9h00-12h00 13h30-16h00Tél: +33(0)4 37 91 54 65 Mail
 Fax: +33(0)4 37 91 54 37
 
- 
						Adresse
						
Auteur Logan K. WINK
|  | 
Documents disponibles écrits par cet auteur (2)
 
                
             
            
                
                     
                
             
						
					
						
							 Faire une suggestion  Affiner la recherche
						
					   Faire une suggestion  Affiner la rechercheBrief Report: Intranasal Ketamine in Adolescents and Young Adults with Autism Spectrum Disorder-Initial Results of a Randomized, Controlled, Crossover, Pilot Study / Logan K. WINK in Journal of Autism and Developmental Disorders, 51-4 (April 2021)

Titre : Brief Report: Intranasal Ketamine in Adolescents and Young Adults with Autism Spectrum Disorder-Initial Results of a Randomized, Controlled, Crossover, Pilot Study Type de document : texte imprimé Auteurs : Logan K. WINK, Auteur ; Debra L. REISINGER, Auteur ; Paul HORN, Auteur ; Rebecca C. SHAFFER, Auteur ; Kaela O'BRIEN, Auteur ; Lauren M. SCHMITT, Auteur ; Kelli R. DOMINICK, Auteur ; Ernest V. PEDAPATI, Auteur ; Craig ERICKSON, Auteur Article en page(s) : p.1392-1399 Langues : Anglais (eng) Mots-clés : Autism Clinical trial Ketamine Index. décimale : PER Périodiques Résumé : Dysregulation of glutamate neurotransmission plays a critical role in autism spectrum disorder (ASD) pathophysiology and is a primary target for core deficit research treatment trials. The mechanism of action of ketamine has striking overlap with the theory of ASD as a disorder of synaptic communication and neuronal networks. This two-dose, double-blind, placebo controlled, cross-over pilot trial of intranasal (IN) ketamine targeting core social impairment included individuals with ASD (N = 21) between 14 and 29 years. Participants were randomized to received two doses of IN ketamine (30 and 50 mg) and two doses of matching placebo. No significant impact was noted on the Aberrant Behavior Checklist Social Withdraw subscale. The IN ketamine was well tolerated, with only transient mild adverse effects. En ligne : http://dx.doi.org/10.1007/s10803-020-04542-z Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=445 
in Journal of Autism and Developmental Disorders > 51-4 (April 2021) . - p.1392-1399[article] Brief Report: Intranasal Ketamine in Adolescents and Young Adults with Autism Spectrum Disorder-Initial Results of a Randomized, Controlled, Crossover, Pilot Study [texte imprimé] / Logan K. WINK, Auteur ; Debra L. REISINGER, Auteur ; Paul HORN, Auteur ; Rebecca C. SHAFFER, Auteur ; Kaela O'BRIEN, Auteur ; Lauren M. SCHMITT, Auteur ; Kelli R. DOMINICK, Auteur ; Ernest V. PEDAPATI, Auteur ; Craig ERICKSON, Auteur . - p.1392-1399.
Langues : Anglais (eng)
in Journal of Autism and Developmental Disorders > 51-4 (April 2021) . - p.1392-1399
Mots-clés : Autism Clinical trial Ketamine Index. décimale : PER Périodiques Résumé : Dysregulation of glutamate neurotransmission plays a critical role in autism spectrum disorder (ASD) pathophysiology and is a primary target for core deficit research treatment trials. The mechanism of action of ketamine has striking overlap with the theory of ASD as a disorder of synaptic communication and neuronal networks. This two-dose, double-blind, placebo controlled, cross-over pilot trial of intranasal (IN) ketamine targeting core social impairment included individuals with ASD (N = 21) between 14 and 29 years. Participants were randomized to received two doses of IN ketamine (30 and 50 mg) and two doses of matching placebo. No significant impact was noted on the Aberrant Behavior Checklist Social Withdraw subscale. The IN ketamine was well tolerated, with only transient mild adverse effects. En ligne : http://dx.doi.org/10.1007/s10803-020-04542-z Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=445 Pediatric Quality of Life Inventory (PedsQL) in Fragile X Syndrome / Sarah E. FITZPATRICK in Journal of Autism and Developmental Disorders, 50-3 (March 2020)

Titre : Pediatric Quality of Life Inventory (PedsQL) in Fragile X Syndrome Type de document : texte imprimé Auteurs : Sarah E. FITZPATRICK, Auteur ; Lauren M. SCHMITT, Auteur ; Ryan E. ADAMS, Auteur ; Ernest V. PEDAPATI, Auteur ; Logan K. WINK, Auteur ; Rebecca C. SHAFFER, Auteur ; Jessica SAGE, Auteur ; Jayne DIXON WEBER, Auteur ; Kelli C. DOMINICK, Auteur ; Craig ERICKSON, Auteur Article en page(s) : p.1056-1063 Langues : Anglais (eng) Mots-clés : Developmental disability Fragile X syndrome Quality of life Index. décimale : PER Périodiques Résumé : To date, health related quality of life (QoL) has not been systematically evaluated in youth with fragile X syndrome (FXS), the most common single gene cause of autism and the most common inherited form of developmental disability. We describe QoL data gathered using the Pediatric Quality of Life Inventory (PedsQL) completed online by 364 parents of youth with FXS. Parents consistently reported across all gender and age groups that their children experienced the highest QoL in Physical functioning and the lowest QoL in Cognitive functioning. Overall, older children with FXS had increase QoL ratings in the domains of School and Cognitive function. En ligne : http://dx.doi.org/10.1007/s10803-019-04292-7 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=420 
in Journal of Autism and Developmental Disorders > 50-3 (March 2020) . - p.1056-1063[article] Pediatric Quality of Life Inventory (PedsQL) in Fragile X Syndrome [texte imprimé] / Sarah E. FITZPATRICK, Auteur ; Lauren M. SCHMITT, Auteur ; Ryan E. ADAMS, Auteur ; Ernest V. PEDAPATI, Auteur ; Logan K. WINK, Auteur ; Rebecca C. SHAFFER, Auteur ; Jessica SAGE, Auteur ; Jayne DIXON WEBER, Auteur ; Kelli C. DOMINICK, Auteur ; Craig ERICKSON, Auteur . - p.1056-1063.
Langues : Anglais (eng)
in Journal of Autism and Developmental Disorders > 50-3 (March 2020) . - p.1056-1063
Mots-clés : Developmental disability Fragile X syndrome Quality of life Index. décimale : PER Périodiques Résumé : To date, health related quality of life (QoL) has not been systematically evaluated in youth with fragile X syndrome (FXS), the most common single gene cause of autism and the most common inherited form of developmental disability. We describe QoL data gathered using the Pediatric Quality of Life Inventory (PedsQL) completed online by 364 parents of youth with FXS. Parents consistently reported across all gender and age groups that their children experienced the highest QoL in Physical functioning and the lowest QoL in Cognitive functioning. Overall, older children with FXS had increase QoL ratings in the domains of School and Cognitive function. En ligne : http://dx.doi.org/10.1007/s10803-019-04292-7 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=420 

